Redipor Success Drives Cherwell Cleanroom Expansion
Cherwell Laboratories, leading supplier of microbiology media and instruments for pharmaceutical and related industries, is continuing with the investment and expansion programme of its cleanroom production facilities. To increase capacity for future demand from Cherwell’s ever growing customer base, Phase II of the expansion programme will boost Redipor microbiological prepared media plate filling and bottle production capabilities. The new cleanroom facility will be further extended by 230 m2 to more than 950 m2.
Once Phase II is completed in early 2014, Cherwell’s facilities will have doubled in size since July 2012. Phase I delivered new inspection and packing facilities to maintain stringent quality requirements in media preparation prior to Phase II’s increase in Redipor production facilities. Uniquely, to ensure utmost quality Cherwell do not package Redipor products straight from the filling line but first hold them to condition, additionally all products then undergo 100% inspection before final packing.
Demand for Cherwell’s Redipor products continues to rise as new customers experience the benefits of a flexible and reliable supply of these exceptionally high-quality prepared media products. Cherwell’s ability to deliver high volume efficiency with small volume flexibility has helped to increase its market share and develop more export markets, such as Poland. Careful selection of new partners in mainland Europe, has also contributed to securing new customers keen to benefit from a full adaptable service for their industrial microbiological prepared media.
Andy Whittard, Managing Director, Cherwell Laboratories, provided further insight into the reasons for Cherwell’s expanding market. “Despite growing interest in rapid methods, the traditional methods for environmental monitoring are still the most widely used and will continue to be for many years to come. This, coupled with some customers’ movement back to UK and European-based manufacturing, is seeing demand for prepared media continue to increase.”
As Cherwell’s production volumes increase from the current 6.5 million agar plates annually, the company will continue to add to its workforce to maintain its efficiency in supply. Cherwell has already recruited five new staff members since the completion of Phase I, with three additional new starters anticipated before the end of 2013.
“Phase II of our cleanroom extension will provide additional manufacturing space to allow us to invest in further production equipment, such as large scale plate filling systems, media preparators and autoclaves,” added Andy Whittard. “By carefully planning and controlling the works around our own production schedules and with our contractor, Envair Projects, we aim to minimise any impact to customers and product lead times.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance